Eyepoint's Phase 3 Trial for Age-Related Blindness Treatment Misses Primary Endpoint

Revelation News Editorial DeskAugust 18, 2026

Source Summary

Eyepoint disclosed that a Phase 3 trial of its experimental treatment for a common cause of age-related blindness failed to meet its primary goal.

Read the Source

STAT News ↗

NASDAQ:EYPTLive chart

Trading trends

The chart totals every SEC-reported transaction by month and share count, separating informative purchases and sales from non-informative awards, vesting, exercises, tax withholding and transfers. Records without a reported price remain included. Only informative purchases and sales affect the conservative sentiment signal.

Recent SEC-reported share and derivative transactions in EyePoint, Inc..

Insider activity sentiment

Leaning bullish

BearishNeutralBullish

1 discretionary purchases · 0 discretionary sales

Confidence: Low

Informative buyNon-informative buyInformative sellNon-informative sell

Insiders	Activity	Description	Shares	Avg. price / share	Est. value	Trade date
Chief Financial OfficerElston George	Non-informative sell	Common StockOther SEC-reported transaction (J)	5,000	—	—	Aug 20, 2026
Chief Financial OfficerElston George	Non-informative buy	Common StockOther SEC-reported transaction (J)	5,000	—	—	Aug 20, 2026
Chief Financial OfficerElston George	Non-informative sell	Common StockGift or transfer (G)	64,953	—	—	Aug 20, 2026
Chief Financial OfficerElston George	Non-informative buy	Common StockGift or transfer (G)	64,953	—	—	Aug 20, 2026
DirectorZaderej Karen L.	Informative buy	Common StockOpen-market or private transaction (P)	10,600	$4.93	$52,258	Aug 18, 2026

As filed with the SEC. Estimated value is shown only for purchases or sales with a positive reported transaction price; awards, gifts and similar activity are not assigned an assumed market value. Amendments may change the record. This is not investment advice.

Short interest

Open short positions reported twice monthly; this is not daily short-sale volume.

Earnings

Recent reported earnings per share compared with the analyst consensus available from Nasdaq.

Comments

No published comments yet.

Owner	Activity	Change	Shares held	Value (thousands)	Reported
Montanova Capital, Llc	Unchanged	0 (0%)	8,296,375	$3,551	6/30/2026
Blackrock, Inc.	Buy	285,860 (3.983%)	7,463,197	$3,194	6/30/2026
Cormorant Asset Management, Lp	Sell	-1,265,000 (-15.306%)	7,000,000	$2,996	6/30/2026
Federated Hermes, Inc.	Buy	11,463 (0.202%)	5,681,052	$2,431	6/30/2026
Adage Capital Partners Gp, L.L.C.	Buy	1,527,792 (46.297%)	4,827,792	$2,066	6/30/2026
Vanguard Group Inc	Buy	1,027,623 (27.082%)	4,822,139	$2,064	12/31/2025
Franklin Templeton Inc	Sell	-241,520 (-4.784%)	4,807,078	$2,057	6/30/2026
Commodore Capital Lp	Buy	1,775,000 (62.832%)	4,600,000	$1,969	6/30/2026
Jupiter Topco Llc	Buy	3,770,381 (New)	3,770,381	$1,614	6/30/2026
Vanguard Capital Management Llc	Buy	70,683 (1.986%)	3,630,252	$1,554	6/30/2026
Janus Henderson Group Ltd.	Buy	663,439 (22.583%)	3,601,168	$1,541	3/31/2026
Paradigm Biocapital Advisors Lp	Sell	-252,040 (-8.021%)	2,890,397	$1,237	6/30/2026

Settlement date	Short interest	Avg. daily volume	Change vs. previous report	Days to cover
Sep 30, 2026	20,788,240	3,863,442	+4.94%	5.38
Sep 15, 2026	19,809,561	3,079,759	+9.38%	6.43
Aug 31, 2026	18,110,761	10,506,239	-1.72%	1.72
Aug 14, 2026	18,426,891	2,024,578	+2.29%	9.10
Jul 31, 2026	18,015,023	1,458,571	+9.68%	12.35
Jul 15, 2026	16,425,378	1,590,009	+8.67%	10.33
Jun 30, 2026	15,114,767	1,572,696	+0.25%	9.61
Jun 15, 2026	15,077,303	1,089,633	—	13.84

Fiscal quarter	Reported	EPS	Consensus	Surprise
Jun 2026	Aug 5, 2026	-1.09	-0.92	-18.48%
Mar 2026	May 6, 2026	-0.99	-0.79	-25.32%
Dec 2025	Mar 4, 2026	-0.81	-0.78	-3.85%
Sep 2025	Nov 5, 2025	-0.85	-0.77	-10.39%

Source Summary

Read the Source

NASDAQ:EYPT — Live chart

Insider activity sentiment

Comments

Related stories

Eyepoint study results for vision treatment disappoint, but company still sees promise

Vera's Trutakna Demonstrates Strong Final Results in Phase 3 Kidney Disease Trial

Roivant's Lung Disease Drug Achieves Mid-Stage Study Goals

Comments

Insider activity sentiment

NASDAQ:EYPTLive chart